Skip to content

Net Income at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.68B+8.8%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.03B+59.6%
Gilead Sciences logo
Gilead SciencesGILD
$2.02B+53.7%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$122.93M+9.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$49.66M-2.4%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$96.23M+15.8%

Other financials

Income statement

See full
Operating income-$48.6M+4.0%
Net income-$47.2M+4.4%
EPS (diluted)-$0.17+19.0%

Balance sheet

See full
Cash & equivalents$83.8M-12.8%
Total debt$75.3M-17.5%
Total equity$119.2M-43.0%
Total assets$373.6M-16.1%

Cash flow

See full
Operating cash flow-$37.4M+23.2%
CapEx$288.0K+112%
Free cash flow-$37.7M+22.8%

Valuation

See full
Market cap$907.23M+54.1%
Enterprise value$898.76M+53.9%

Returns & leverage

See full
Return on equity-147.4%-2,468pp
Debt / equity0.6×+0.2×
Current ratio1.3×-2.1×

Where this comes from

Reported directly by Sana Biotechnology in its filing.

Tagged under the XBRL concept us-gaap:ProfitLoss.

The official record: Sana Biotechnology’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sana Biotechnology's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sana Biotechnology's net income?
Sana Biotechnology (SANA) reported net income of -$47.21M in Q1 2026.
How has Sana Biotechnology's net income changed year-over-year?
Sana Biotechnology's net income increased by 4.4% year-over-year, from -$49.39M to -$47.21M.
What is the long-term trend for Sana Biotechnology's net income?
Over 4 years (2021 to 2025), Sana Biotechnology's net income has grown at a -10.1% compound annual growth rate (CAGR), from -$374.61M to -$244.17M.
What does net income mean?
Net income as the starting point for the indirect method operating cash flow reconciliation.